Study Start-Up

At ProPharma, we approach study start‑up as an integrated, fit‑for‑purpose strategy and not a handoff between functions. From early country selection and feasibility through first patient in (FPI), our focus is on translating early insights into realistic timelines, aligned execution, and predictable activation across regions and sites.

Why Study Start‑Up So Often Slips

Country selection and feasibility are frequently treated as discrete activities: sites complete questionnaires, countries are selected, and timelines are modelled. In practice, this sequential approach often misses critical, localized signals:

• Site enthusiasm does not always align with site readiness
• Regulatory and ethics timelines vary significantly by region and country
• Contracting, budgets, and internal site processes are often underestimated
• Key risks surface after study award and project kick‑off, when options are already limited

The result is familiar: late‑stage changes, compressed timelines, and avoidable delays that impact both cost and confidence. This is rarely a failure of effort but a consequence of viewing study startup in silos rather than as a connected whole.

A Different Way to Think About Study Start‑Up

Effective study startup is not driven by templates alone. It requires a deep understanding of regional and local realities and a structured, tight relationship between cross functional teams.

This means recognizing how regulatory pathways differ across countries, how sites truly operate day‑to‑day, and how local constraints influence readiness and sequencing. It also means relying on teams with boots‑on‑the‑ground experience, people who understand not just the rules, but how those rules are applied in practice.

At ProPharma, study startup is approached holistically. Our teams bring extensive local knowledge together within a connected global structure, enabling informed decisions early when they matter most.

This perspective shifts study startup from a series of tasks to a coordinated system of people, insight, and execution.